文献速递神经免疫认知障碍与痴呆

多发性硬化脊髓的神经变性与脱髓鞘:临床、病理与7T MRI视角

Neurodegeneration and Demyelination in the Multiple Sclerosis Spinal Cord: Clinical, Pathological, and 7T MRI Perspectives.
PubMed 文献 · Neurology · 2025-03-13

本研究利用多发性硬化(MS)患者死后颈髓标本,结合7T MRI与免疫组化,发现T2*阈值可准确区分脱髓鞘(准确率89.7%),且T2*高信号/脱髓鞘病灶与EDSS及颈髓面积相关;而T2*高信号/髓鞘保留区存在髓鞘和轴索病理,提示神经变性。

要点

  • 7T T2*阈值区分脱髓鞘的准确率89.7%,灵敏度95.5%,特异度87.0%。
  • T2*高信号/脱髓鞘病灶与EDSS(rho=0.61)和上颈髓面积(rho=-0.64)相关。
  • T2*高信号/髓鞘保留区显示髓鞘减少、轴索计数下降,提示神经变性。

核心结论

  • 7T T2*死后MRI阈值可有效区分脱髓鞘病灶,且与临床残疾和脊髓萎缩相关。
  • T2*高信号/髓鞘保留区在斑块周围或沿传导束分布,表现出髓鞘和轴索病理,提示神经变性。

研究设计与样本

  • 横断面研究,使用克利夫兰诊所MS快速尸检项目的死后颈髓节段。
  • 纳入40例MS(中位年龄58,女性55%)和9例对照(中位年龄69,女性89%)。
  • 组织移除和固定前进行原位MRI,随后进行7T MRI和免疫组化。

主要发现

  • T2*阈值区分脱髓鞘的准确率89.7%,灵敏度95.5%,特异度87.0%。
  • 髓鞘含量是T2*的唯一显著预测因子(95% CI -0.82至-0.58,估计值-0.70)。
  • T2*高信号/髓鞘保留区较正常表现MRI区域:T2*弛豫时间增加19.2 ms(95% CI 9.97-28.4),髓鞘含量减少8.3%(95% CI -12.1至-4.4),MHCII增加3.6%(95% CI 0.45-6.7),轴索计数减少349.8(95% CI -565.4至-134.1),轴索面积增加2.0 µm²(95% CI 1.0-3.1)。
  • T2*高信号/脱髓鞘病灶与EDSS相关(rho=0.61,p<0.0001),与上颈髓面积相关(rho=-0.64,p<0.0001);T2*高信号/髓鞘保留区无此相关。
  • 7T死后T2*高信号在临床1.5T轴位T2上表现细微,矢状位仅43%被检测到。

临床怎么用

  • 7T T2*阈值可用于区分MS脊髓脱髓鞘病灶,这些病灶与临床残疾和脊髓萎缩相关。

局限性

  • 采样每位参与者2 cm脊髓,难以对近端和远端病理得出结论。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Key findings in people with multiple sclerosis (MS) with progressive motor disability are spinal cord (SC) atrophy signifying irreversible axonal loss and SC demyelinated lesions. This study aimed to identify neurodegenerative changes and assess the clinical impact and pathologic characteristics of SC lesions. METHODS: A cross-sectional study was performed using postmortem cervical cord segments from the Cleveland Clinic MS Rapid Autopsy Program. Inclusion included proximity to our center, absence of transmissible infections, and lack of prolonged hypoxia. In situ MRIs were performed before tissue removal and fixation followed by 7T MRI and immunohistochemistry. Quantitative T2* relaxation times were correlated with myelin, axons, and activated microglia/macrophages (major histocompatibility complex II [MHCII]) using Tukey comparison of means and a linear mixed-effects model; T2* was correlated with clinical disease characteristics using Wilcoxon rank sum. RESULTS: The study included 40 MS cases (median age 58, female 55%) and 9 controls (median age 69, female 89%). A T2* threshold reliably discriminated demyelination (accuracy 89.7%, sensitivity 95.5%, and specificity 87.0%). Myelin content (95% CI -0.82 to -0.58, estimate -0.70) was the only significant predictor of T2*. T2* hyperintensities within the segments ranged from 0% to 100% (median 33.6, interquartile range 12.9-64.3) with only 57.1% demyelinated. T2*-hyperintense/myelinated regions had increased T2* relaxation time (19.2 ms, 95% CI 9.97-28.4), reduced myelin content (-8.3%, 95% CI -12.1 to -4.4), increased MHCII (3.6%, 95% CI 0.45-6.7), reduced axonal counts (-349.8, 95% CI -565.4 to -134.1), and increased axonal area (2.0 µm2, 95% CI 1.0-3.1) compared with normal-appearing MRI regions. These regions occurred adjacent to T2*-hyperintense/demyelinated lesions (periplaque) or along tracts (tract-based). 7T postmortem T2* hyperintensities were subtle on clinical 1.5T axial T2, and only 43% were detected sagittally. T2*-hyperintense/demyelinated lesions correlated with Expanded Disability Status Scale (EDSS) (rho = 0.61, p < 0.0001) and upper cervical cord area (rho = -0.64, p < 0.0001) while T2*-hyperintense/myelinated regions did not. DISCUSSION: Thresholding 7T T2* postmortem MRI can effectively discriminate demyelinated lesions which correlate with clinical disability and cord atrophy. T2*-hyperintense/myelinated regions exhibit myelin and axonal pathology in periplaque or tract-based distributions suggestive of neurodegeneration. Limitations include sampling of 2-cm of SC across participants making conclusions about proximal and distal pathology difficult.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Mahajan KR, Herman D, Zheng Y, et al. Neurodegeneration and Demyelination in the Multiple Sclerosis Spinal Cord: Clinical, Pathological, and 7T MRI Perspectives. Neurology. 2025. PMID: 40080735. doi:10.1212/WNL.0000000000210259

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。